Status:
TERMINATED
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
Lead Sponsor:
Centre Oscar Lambret
Conditions:
Anal Cancer
Anxiety Disorder
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standar...
Detailed Description
OBJECTIVES: Primary * To compare the psychological and emotional consequences in patients who underwent first-line antitumor treatment (chemotherapy or targeted therapy) for metastatic disease while...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed cancer
- Metastatic disease for which the median progression-free survival is ≥ 4 months
- Breast, digestive, kidney, lung
- Receiving first-line antitumor therapy (i.e., chemotherapy or targeted therapy) as part of either:
- Phase II or III randomized clinical trial
- Standard treatment off-trial
- PATIENT CHARACTERISTICS:
- WHO performance status (PS) 0-3 or Karnofsky PS 50-100%
- No psychological or physical inability to respond to a questionnaire
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No psychotropic treatment, except for antidepressants, anxiolytics, or sleeping pills taken for more than 30 days
Exclusion
Key Trial Info
Start Date :
September 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2010
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00896467
Start Date
September 1 2007
End Date
November 1 2010
Last Update
July 10 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Oscar Lambret
Lille, France, 59020
2
Laboratoire URECA
Villeneuve-d'Ascq, France, 59653